$GKOS

Thurman Alex R. sold $3.6M of GKOS

Thurman Alex R. (SVP & CHIEF FINANCIAL OFFICER) sold 20,000 shares of GLAUKOS Corp (GKOS) at $180.13 ($3.60M total) on 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Thurman Alex R.
Published Aug 11, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 9:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The newest disclosed fact is the Aug 7 open-market sale of 20,000 shares by the CFO, filed Aug 11, with holdings after the sale of 43,906 shares.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying operational or financial news.

03

What to watch

The filing does not disclose reasons for the sale, and the presence of a pre-arranged plan often limits interpretability for traders.

Relevance 5/10Novelty 3/10Timing: filed Aug 11, transaction dated Aug 7

Background

The article is an SEC Form 4 insider transaction disclosure for Glaukos (GKOS).

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Glaukos CFO Thurman Alex sold 20,000 shares in an open-market transaction for about $3.6M under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless paired with other news.

Evidence & confidence

Form 4 details an open-market sale by an officer with a stated 10b5-1 plan, which typically reduces signaling value versus discretionary selling.

Market effects

Minimal; insider-sale Form 4s rarely change sector fundamentals.

None indicated.

None indicated.

Counterpoint

The sale could be driven by diversification or tax planning under the 10b5-1 plan, so it may not reflect bearish expectations.

Key entities

  • GLAUKOS Corp

    Company whose insider transaction is disclosed on Form 4.

  • Thurman Alex R.

    SVP and Chief Financial Officer who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.